

BICO Announces Appointment of Susan Tousi as New Member of the Board of Directors

Susan Tousi currently serves as Chief Commercial Officer at Illumina and will bring more than a decade of life science industry experience to the fast-growing Bio Convergence company

Today BICO, the world's leading Bio Convergence company announced it has added Susan Tousi to its Board of Directors. Tousi has spent nearly a decade at Illumina, where she currently leads the global commercial organization. Tousi was approved unanimously during an Extraordinary General Meeting (EGM) of the Board of Directors.

"I've come across hundreds of life science companies during my career, but BICO's approach to converging biology and technology is unlike anything I've seen," said Susan Tousi, Chief Commercial Officer of Illumina and Member of the Board at BICO. *"In many ways it reminds me of our ambitions at Illumina to drive innovation that will transform human health, so I'm incredibly excited to dive in and start contributing."*

Illumina is world leading in DNA sequencers and advancements in genomics are poised to drive significant healthcare breakthroughs in the coming decades. Illumina's efforts have already significantly bolstered the global response to the COVID-19 pandemic. A field that is also vitally important to BICO's business, with nearly all its subsidiaries selling into the industry. As the leader of Illumina's commercial organization, Tousi will bring invaluable strategic insights and recommendations that enable BICO to become a leading player in the field.

"We are very happy to welcome Susan Tousi to the Board of Directors at BICO Group. Susan Tousi has built some of the most groundbreaking and innovative technologies the life sciences industry has ever seen, ones that are poised to save millions of lives in coming decades," said Erik Gatenholm, CEO and co-founder of BICO. *"Our mission at BICO is to save lives and create the future of health by converging biology and technology, and I am confident that Susan Tousi's addition will accelerate our ability to do that."*

Tousi has been with Illumina since 2012, and previously led the product development organization as Chief Product Officer. During that time, she was responsible for global engineering, consumables, sequencing applications, IVD, software and informatics development efforts as well as overseeing numerous key product launches and leading the acquisition of Edico Genomics, BlueBee, and Enancio.

Susan Tousi brings more than 25 years of R&D and business leadership experience at Fortune 100 technology companies, and within the life sciences industry. Prior to Illumina, Susan Tousi held leadership positions at Eastman Kodak and Hewlett-Packard. Susan Tousi has received numerous awards in business and technology including being elected to the National Academy of Engineering in 2018 and being named one of the 50 Top Diverse Leaders by the California Diversity Council in 2020.

For more information about Tousi's appointment and the Board of Directors, please visit:
<https://bico.com/investors>

For further information, please contact:

Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email: il@bico.com

BICO Press office

Phone (US):
Riley Munks, PR Manager: (650) 863-6699
Alyssa D'Orazio, PR Manager: (617) 634-9601
Email: press@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on November 17, 2021, at 6pm (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com